Myovant Sciences (MYOV) Reports Prelim Q3 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St on track for subdued September start as high yields, oil prices dent sentiment
- Oil up more than 2% as renewed US-Iran strikes stoke supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
Myovant Sciences Announces Preliminary Financial Results for Third Quarter of Fiscal Year 2021
January 10, 2022 6:55 AM ESTEstimated total revenue of $54.0-$55.0 million, including net product revenue of $28.8-$29.8 millionEstimated ORGOVYX® net product revenue of $24.2-$24.6 million, reflecting 40% sequential volume growth compared to fiscal second quarter 2021, partially offset by a lower net price Estimated MYFEMBREE® net product revenue of $2.3-$2.6 million; New-to-brand prescription (NBRx) share among GnRH antagonist therapies FDA-approved for the treatment of uterine fibroids grew to 45% in December 2021, six months... More
